beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme...

Area of Science:

• Cardiology
• Clinical Research
• Pharmacology

Background:

• Beta-blocker (BB) use is known to reduce infarct size in nonreperfused myocardial infarctions.
• Its effect on infarct size in patients receiving reperfusion therapy, such as percutaneous coronary intervention (PCI), is less clear.
• Previous studies suggested BB use concurrent with PCI might decrease creatine kinase (CK)-MB elevation, but required robust risk adjustment.

Purpose of the Study:

• To evaluate the association between pre-PCI beta-blocker (BB) use and myocardial injury.
• To determine if BB use prior to PCI influences creatine kinase (CK) and CK-MB levels.
• To assess the impact of BBs on myocardial damage in patients undergoing PCI, accounting for baseline differences.

Main Methods:

• A large observational study analyzed 6200 consecutive patients undergoing PCI.
• Propensity score and multivariate regression analyses were employed to adjust for baseline differences between patients with and without BB treatment.
• Per-protocol measurements of creatine kinase (CK) and CK-MB were assessed in relation to BB use.

Main Results:

• Patients on BBs had significantly higher baseline levels of CK and CK-MB compared to those not on BBs.
• Despite higher baseline enzyme levels in the BB group, maximum CK and CK-MB levels were not significantly different between groups after adjustment.
• Statistical analysis showed no significant difference in maximum CK rise (P=0.21) or maximum CK-MB rise (P=0.99) between BB users and non-users.

Conclusions:

• This study's findings do not support the hypothesis that beta-blocker use before PCI reduces myocardial injury.
• The observed higher CK and CK-MB levels in BB users were likely due to baseline differences, not a direct effect of BBs on infarct size.
• Current evidence does not advocate for routine BB use prior to PCI to limit myocardial damage.